EpimAb Biotherapeutics Submits Hong Kong IPO Application as Biotech Expands
Shanghai-based biotech EpimAb Biotherapeutics, Inc. has submitted a main board listing application to the Hong...
EpimAb Biotherapeutics
EpimAb Biotherapeutics and Juri Biosciences Ink Global Licensing Deal for KLK2-CD3 T-Cell Engager
Shanghai-based biotech EpimAb Biotherapeutics announced a global licensing agreement with US-headquartered Juri Biosciences, Inc., a...
NewCo Model: China’s Innovative Drug Companies’ New Transaction Mode in Capital Winter
NewCo is a new transaction model developed by Chinese innovative drug companies in response to...
EpimAb and Medigene Team Up on TCR-TCE Therapy for Immune-Related Diseases
EpimAb Biotherapeutics, Inc. and Medigene AG (ETR: MDG1) today announced a strategic collaboration agreement to...
Candid Therapeutics Expands TCE Portfolio with Strategic Partnerships in Autoimmune Disease Treatment
US-based Candid Therapeutics Inc. is fulfilling its ambition to become a leader in advancing T-cell...
EpimAb’s EMB-06 Secures $635 Million Licensing Agreement with Vignette for Multiple Myeloma Therapy
EpimAb Biotherapeutics, a Shanghai-based biotech firm, has inked a licensing deal with Vignette for the...
EpimAh Biotherapeutics to Present First-in-Human Results for EMB-06 at SITC Annual Meeting
Shanghai-based biotechnology company EpimAb Biotherapeutics has announced that it will present first-in-human results for its...
EpimAb Biotherapeutics Licenses Bispecific Antibody Platform to Almirall
Shanghai-based EpimAb Biotherapeutics has entered into a strategic license agreement with Spanish pharmaceutical company Almirall...
EpimAb Biotherapeutics Appoints Dr. Zhu Yonghong as Chief Medical Officer
Shanghai-based biotech company EpimAb Biotherapeutics has announced the appointment of Dr. Zhu Yonghong to the...